Answers are grounded in this paper and cite their sources.
Demonstrates that oral phenylindandione induces prothrombopenia and undergoes catabolism more rapidly than dicumarol, highlighting its potential as an alternative anticoagulant.
Heparin and dicumarol are both useful drugs but each has its limitations and accordingly search goes on for newer drugs that lack some of these limitations. A new anticoagulant, phenylindandione produces a prothrombopenia more rapidly than dicumarol and its catabolism is equally more rapid. This, therefore, aroused interest in clinical trials utilizing this new prothrombopenic agent. The drug is a light yellow, crystalline compound put up in tablet form and administered by mouth.
No takes yet. Share an insight, caveat, or question.
BLAUSTEIN et al. (1950) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: